{"ticker": {"uuid": "0913a744-b395-45ab-84dc-67f6eeac2e8f", "symbol": "NUVB", "name": "Nuvation Bio Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvation Bio\u2019s Global Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1vWXJKRW5xNnpLZzRkRDltY1M0V0hualY2QVpNaW9Xc0NGSTlzSTZuWnZZUTJJVWNPYS1VZGxtbThmS1hlWmdVaEpFQ3BjMjhYQzhXY3BqSzlQclQ2Z1M4eVJtNUZfdDJiT3BF?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-07-15T10:03:15+00:00", "published_display": "15 Jul 2026 10:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPYlhzWHNLSkNucGJrb0ZONXhNZW1EVm13Y1kxSFo0c1U5OXdNLXd2bklIRW9hLVpWSHUzeU5nejB1UnFSV3lmdVNWM21ZdUhvcURjcy1HTnc5aGNXNjAySjVubnFmT1g3bVR0QUxnZzlWbTZvY3Y4Y3ZXZ3hZZ0RlS1d3TQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T08:32:44+00:00", "published_display": "15 Jul 2026 08:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNWWRTSGJzRnIxYl9KNThLQU1kbUdua01DTU9aeUp0WWZHazl0QjlmaGtIdjNQTjE0QWFybnU1cHBxaVJHRG50MmUwdzZEOFhKRVFTeERjaTJSQjlDb3pPSklrU1BDV2kzYVJwNU00RmJtM05FQWNQUlRVRVkweUZwRzZWUUF0WXhTZTk3NkhDLXdBV0dYdTRfeERwcUhwaVRlWWNnUDhrZFRDSlhMZ2RvLVJWMTZGYmZXZWxuTi1OOEV5ZlBjNE5HSDJxQXJVcGhWMEZXMXV5bFhHUTNFUm5keQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-14T05:38:00+00:00", "published_display": "14 Jul 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio (NUVB) Fairly Valued Following UK Taletrectinib Filing Progress?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-13T19:46:00+00:00", "published_display": "13 Jul 2026 19:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOcFBVVi1URkdvVmh0eGRWWUNYX1puemJTWnk4dEVza1JFS0xFREZnOEEwSUpYYnM5bkM3RElzVzRvb1NwVFdsQTlERzVNQ2QweldrM1hpaklrSVlsbGdNZFBBZG9XbTJCYlZINXRzS1pBMDdnRDdPTWxJeFdFclZBSHVaa2dCQXgtYXl3M3pTcWpxWmhZYmhv?oc=5", "source_name": "Market source", "published_at": "2026-07-13T09:28:51+00:00", "published_display": "13 Jul 2026 09:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE", "summary": "This page provides live quotes and charts for Nuvation Bio Inc. Class A (NUVB) stock, showing its current price of $6.11, an increase of $0.24 (4.09%). It indicates that analyst ratings and earnings information for NUVB are not currently available. The page also includes disclaim", "url": "https://timothysykes.com/quote/NUVB/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:40:28", "published_display": "10 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvation Bio (NUVB) Have the Global Scale to Maximize Taletrectinib\u2019s Regulatory Momentum?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T13:40:03+00:00", "published_display": "09 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-nuvation-bio-120838638.html", "source_name": "MT Newswires", "published_at": "2026-07-07T12:08:38+00:00", "published_display": "07 Jul 2026 12:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering", "summary": "Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or \"Greenshoe Exercise,\" to purchase an additional $37.5 million of its 0.75% Convertible Senior Notes due 2032. This brings the total offering to $287.5 million. The net proceeds,", "url": "https://sg.finance.yahoo.com/news/nuvation-bio-inc-announces-full-210900758.html", "source_name": "Market source", "published_at": "2026-07-06T21:13:52", "published_display": "06 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total common shares outstanding of Nuvation Bio, Inc. Class A \u2013 FWB:1E30", "summary": "This article provides details on the total common shares outstanding for Nuvation Bio, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:1E30. It indicates that the market was closed with no trades when the information was accessed. The page also features ", "url": "https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/total-shares-outstanding/", "source_name": "TradingView", "published_at": "2026-07-04T05:10:16", "published_display": "04 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nuvation Bio, Inc. Class A \u2013 FWB:1E30", "summary": "This article provides financial information for Nuvation Bio, Inc. Class A (FWB:1E30) on the Frankfurt Stock Exchange. It specifically highlights the \"Price to earnings forward\" metric for the company. The page appears to be a financial data presentation without detailed analysis", "url": "https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T19:40:48", "published_display": "03 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Nuvation Bio, Inc. Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Nuvation Bio, Inc. Class A stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment focuses inclu", "url": "https://www.tradingview.com/symbols/FWB-1E30/etfs/", "source_name": "TradingView", "published_at": "2026-07-03T17:09:47", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvation Bio\u2019s (NUVB) U.K. Taletrectinib Milestone Hint at Durable Global Oncology Positioning?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T10:42:51+00:00", "published_display": "01 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio\u2019s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZGJsT2ZOVS1aejJ2V3c2bnlab2RaWTN5TERlNmhmNVktUVllOURmbjk1ZEZxcE9KT0NhQ2lJODFERlk2VzNWT3pyMkdPV1JQTFdZaTBPVFBoSTVwWVRQb05PSVhIeEtsMUM1dEkzLWdYSlQta3hsSnB1TlpuellIckxYbVpwdFU2aWY3M1N1cFMxSVd3Q3VnbjZVUEM1dzY5OFppXw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nuvation-bio-faces-more-predictable-190809469.html", "source_name": "MT Newswires", "published_at": "2026-06-30T19:08:09+00:00", "published_display": "30 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?", "summary": "", "url": "https://finance.yahoo.com/m/0935449e-7333-36f6-afc0-633652ca661b/nuvation-bio-stock-is-up-190%25.html", "source_name": "Motley Fool", "published_at": "2026-06-29T23:39:05+00:00", "published_display": "29 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio's Taletrectinib Enters UK Regulatory Review", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nuvation-bio-apos-taletrectinib-enters-123720021.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:37:20+00:00", "published_display": "29 Jun 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio clears first U.K. regulatory step for lung cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLXhDWVBKMGpuRVY5bTIyTTFZZmpQdTU0Sm0wVU9haml0bW4wVHRWNTZJVVl3Rm5YZ0tUN3NzZnktUlpPdHZGVmplWDByb2Q3SGJGSTdCTm9kNHVtRk9nQk8tT0szT0dseXhKRE9wbmhIdFp4S1diMWJvMWdrWDAzc0cydHozNGZMZDhJemZLZzVILUMzblpaZEdsdGF1MjVDVmwyVlRhUVJ6QnZNU0M5TVdmeDdRWHQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB)", "summary": "This article provides an overview of Nuvation Bio Inc. (NYSE: NUVB) stock performance, financial estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnin", "url": "https://www.tradingview.com/symbols/NYSE-NUVB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:16", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes", "summary": "Nuvation Bio Inc. has announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due in 2032. The net proceeds, estimated at approximately $241.2 million, will be used to pay for capped call transactions, repay a senior secured l", "url": "https://www.prnewswire.com/news-releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes-302811504.html", "source_name": "PR Newswire", "published_at": "2026-06-26T04:10:55", "published_display": "26 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Announces Proposed Convertible Senior Notes Offering", "summary": "Nuvation Bio Inc. announced its intent to offer $200.0 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30.0 million. The company plans to use the proceeds to cover capped call transactions, repay its senior secured loan,", "url": "https://investingnews.com/nuvation-bio-announces-proposed-convertible-senior-notes-offering/", "source_name": "Investing News Network", "published_at": "2026-06-26T03:10:56", "published_display": "26 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio\u2019s chief people officer sells $753k in stock", "summary": "Nuvation Bio's Chief People Officer, Markel Stacy, sold 125,000 shares of Class A Common Stock for $753,187, following the exercise of stock options. This sale was part of a pre-arranged trading plan, occurring after the company's stock surged 215% over the past year. Nuvation Bi", "url": "https://m.investing.com/news/insider-trading-news/nuvation-bios-chief-people-officer-sells-753k-in-stock-93CH-4759410?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T23:10:26", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio prices $250M convertible notes offering", "summary": "Nuvation Bio Inc. has priced an upsized offering of $250 million in convertible senior notes due in 2032, increasing from a previously announced $200 million. The biotech company will use the proceeds to pay for capped call transactions, repay its existing senior secured loan of ", "url": "https://www.investing.com/news/company-news/nuvation-bio-prices-250m-convertible-notes-offering-93CH-4761987", "source_name": "Investing.com", "published_at": "2026-06-25T21:09:57", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio CFO Sauvage sells $286k in stock", "summary": "Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan. This transaction occurred after he exercised stock options to acquire the shares. Following the sale, Sauvage holds 12,673 direc", "url": "https://www.investing.com/news/insider-trading-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4759391", "source_name": "Investing.com", "published_at": "2026-06-25T13:40:16", "published_display": "25 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio CFO Sauvage sells $286k in stock By Investing.com", "summary": "Nuvation Bio Inc.'s CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan, after exercising stock options. Despite a significant stock surge, InvestingPro suggests the shares might be overvalued. Th", "url": "https://m.au.investing.com/news/stock-market-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4503569?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-25T05:10:33", "published_display": "25 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio chief regulatory officer sells $379k in stock", "summary": "Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of company stock worth $379,190 on June 23, 2026, following the exercise of stock options. This sale was conducted under a 10b5-1 trading plan and comes after a significant 215% surge", "url": "https://m.investing.com/news/insider-trading-news/nuvation-bio-chief-regulatory-officer-sells-379k-in-stock-93CH-4759395?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T23:10:26", "published_display": "24 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Nuvation Bio Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQUlZ6dlB5Tkc1bkJTcTFmTTN1N3pSR3RFN3ZuajJlSUVZcXJGZUNMU2hyMDU3MFBKRzZfU1R3SXpsX0JtYzZxZWFDRUY2Rk5JR05WVWFuRURtNDhYZUNIb0Q4Um9FeVd4YVBNSVNhVEJtTTE4MHpLRmtuaXJTRVdneWtfem9Xa3JkY3pQYXQtSzM5QW5ZVkp5Nw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdGpMbmRGd0g0eU9OanhzdTNGNlFIOF83dGszMmNnTXFTR0VVaEVTSkgtR2NzMkxjNmtFSmQ0eVdWbEtySElkMmh4VkRqLURHN1VvejFaclBNLVg1dElma2tQbW82aVU3Z3RIR1pqRHRhWGlKd3pXdjBVRVRCV2xvWGdZeFVfM2RoeFB1V2V4b0R1dHl1U044eWdhMnpzclhqLW1WNWZXMA?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio director Robert Mashal buys $118,250 in stock", "summary": "Robert Mashal, a director at Nuvation Bio Inc. (NASDAQ:NUVB), recently purchased 25,000 shares of the company\u2019s Class A Common Stock for $118,250 through his revocable trust. This transaction increases his indirect ownership to 225,000 shares. The purchase comes as InvestingPro a", "url": "https://www.investing.com/news/insider-trading-news/nuvation-bio-director-robert-mashal-buys-118250-in-stock-93CH-4738706", "source_name": "Investing.com", "published_at": "2026-06-12T00:39:09", "published_display": "12 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director\u2019s trust buys 25,000 Class A shares", "summary": "Nuvation Bio director Robert Mashal, through his revocable trust, purchased 25,000 shares of Class A Common Stock at $4.73 per share in an open-market transaction. This acquisition increases the trust's total holdings to 225,000 shares of Nuvation Bio Class A Common Stock. The tr", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-e33ac05134c3.html", "source_name": "Stock Titan", "published_at": "2026-06-11T23:39:29", "published_display": "11 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) (NYSE:NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPQ1MtQ3VidVdpNW03ZS1ubVFnVFZoeTdZTU91ZEY2RUFpdDliNmxQRXh3d0VJdlZpU1dQQTFfQUticXJrV1drNzZlS1A2dzEzc01ucTRFQUZhVHR3ejZVeVdRMm1xcWtxYUQ0eVF0Y1J0QTNyR1BKX2gtZWJaVjRNLXRKWUVSWFR0dkFSLXM2NkpyYXYxUTItVw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay", "summary": "Nuvation Bio Inc. (NUVB) announced the results of its 2026 Annual Meeting. Shareholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff, to serve until the 2029 annual meeting. Additionally, KPMG LLP was ratified as", "url": "https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-d1aee89d2c0a.html", "source_name": "Stock Titan", "published_at": "2026-05-28T14:39:04", "published_display": "28 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results", "summary": "Nuvation Bio Inc. filed an 8-K form with the SEC, detailing the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as auditor, and an advisory vote on executive compensation. The repor", "url": "https://www.minichart.com.sg/2026/05/28/nuvation-bio-inc-files-form-8-k-with-sec-detailing-company-information-and-annual-meeting-results/", "source_name": "Minichart", "published_at": "2026-05-28T11:40:08", "published_display": "28 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing", "summary": "Nuvation Bio Inc. director Xiangmin Cui's insider trading report has been corrected through an amended Form 4 filing, revealing he was granted 76,923 stock options for Class A common stock on February 27, 2026. This rectifies an administrative error in a previous filing that repo", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-a-nuvation-bio-inc-amended-insider-trading-activity-f55e98598bfa.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036", "summary": "Nuvation Bio (NUVB) director Xiangmin Cui was granted 123,397 stock options with an exercise price of $4.79 per share, expiring on May 20, 2036. These options represent a compensation-related acquisition and will fully vest on the earlier of May 21, 2026, or the next shareholder ", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-2f2714f8cd0c.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79", "summary": "Nuvation Bio Inc. director Robert B. Bazemore was granted 123,397 stock options for Class A common stock with an exercise price of $4.79 per share, expiring on May 20, 2036. The options will vest 100% on May 21, 2026, or the next annual shareholder meeting, contingent on his cont", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-ca8bf6a19015.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Nuvation Bio (NASDAQ: NUVB) awarded 123,397 stock options", "summary": "Robert Mashal, a director at Nuvation Bio (NASDAQ: NUVB), was granted 123,397 stock options with an exercise price of $4.79 per share. These options will vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, provided he maintains continuous service. Th", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-079aaa1cf63f.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio to Present New Quality-of-Life Data for IBTROZI\u00ae (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting", "summary": "Nuvation Bio will present new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI\u00ae (taletrectinib) at the ASCO 2026 Annual Meeting. The data shows that 88% of patients with ROS1-positive non-small cell lung cancer (NSCLC) reported improved or stable quality ", "url": "https://www.prnewswire.com/news-releases/nuvation-bio-to-present-new-quality-of-life-data-for-ibtrozi-taletrectinib-in-patients-with-ros1-positive-non-small-cell-lung-cancer-at-asco-2026-annual-meeting-302782377.html", "source_name": "PR Newswire", "published_at": "2026-05-25T11:40:10", "published_display": "25 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) Proxy filing Summary", "summary": "Nuvation Bio (NUVB) has scheduled its Annual Meeting for May 21, 2026, where stockholders will vote on electing three directors, ratifying KPMG LLP as the auditor for 2026, and an advisory vote on executive compensation. The board recommends voting in favor of all proposals. The ", "url": "https://quartr.com/events/nuvation-bio-inc-nuvb-proxy-filing_FL4uRymA", "source_name": "Quartr", "published_at": "2026-05-18T22:10:08", "published_display": "18 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvation Bio (NYSE:NUVB) - Stock Analysis", "summary": "Nuvation Bio (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on cancer treatment. The company recently reported a surprise statutory profit in Q1 2026, exceeding analyst expectations, and its lead product candidate, IBTROZI (taletrectinib), has received FDA appr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio", "source_name": "Simply Wall Street", "published_at": "2026-05-14T20:15:24", "published_display": "14 May 2026 20:15", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvation Bio partners with Thermo Fisher for US drug manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTGpYVHRwR1hTVkxCRXFnRHQtRWF6NFBQMldMQk9KOUZPUC1WdkhBaWQxRFRHS3ZfTVJYVkNxSXFrRVlVR25ibmJwS2xydFVmbFE0UjNRbEMxbnJadFkxQm1DOElVNHpteEpLc1VUR0VuMWdFQlFkTmItVjB4YkhzbW1KT0puVkdNTW5fUzJldzBCXzJCaWhLS2U4RFYxeDhYdDdMSlJqN0xLLW90aGo3ckNFdTdzT0JFaG93bEl2eFY?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit", "summary": "Nuvation Bio Inc. (NYSE: NUVB) shares rose 8.1% after reporting a surprise profit of US$0.01 per share and revenues of US$83m for the first quarter, significantly exceeding analyst expectations. Analysts have increased their price target to US$12.33 and reduced their loss per sha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/results-nuvation-bio-inc-confounded-analyst-expectations-wit", "source_name": "Simply Wall Street", "published_at": "2026-05-13T00:10:08", "published_display": "13 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE8wX0hRWFNvTHlDNWhnNUNVYVl6ZGI4cVNacGFod3luQ1c3dHltakM4dlUxLXlPRFJiaVZsZXZLak9tVENHYy1sV1lrYm9NTGlNSjh2bjlKaGt0VlZLR282NmdzaHdnYzU4WVRaWUtHNkNYSkp3c24tMVZxT0RkOVE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nuvation Bio's CEO and CFO line up four investor webcasts in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOQkYtczR5eG55VW5QbHBMekRHeEVCZ1BOZjN2Ni1QU1JwNjJiMThLMHVIYlpqMl9BbDlHT1VzMXo5LUNvVEExR184cE9fWWtBRTVGQ1E1RmQtSnJBWGdjXzNXbEdQVkdHSjAyM3Z2allzeXBzVHEwV1E2TlhvNUZMM284TVVrOWtZamRleWFMOThJZUdfOHNyZWkyMVo4NjRLSGMtS0FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNmdrLXhCLV90eHBKM0xwd0ZiLWdxbFo3QnhSZTJUd25LdjZydEo5NlN5OUZ0dXlCLWItamJBQkNFVWIzN1c3UlVBZDEwM1BHMlhscE9BSm5Eano4UjVuV2tfamowem1TX0dKbVk4S3NqNlU1a3B3blZUd2poTThiYl9xRzlNTXR3UXhSazFudWprNHNaM09CRzgxc2hqQUpadER3ODNTS0RQZWNoVVZOc0h2R0UtVzNRcVByT2t0MVZNRFFlZjVxQmtjNl9aQXhLUnVwaDNXSnVOUQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQV2paQ3gwTmhTZmRUT3RBMjRtUEYyR3VvWG5qaExJTDROaWdEa3ZoZk13N1NnTmU1SENxRk05aEVoa0JleWtsNkZldEpsekFERTRFVlhEbE84YWcwQTFPZlF0ZUFTbGcwb2xhd2RTa0VBLUdzU2l6d0JQUWZzcUloZERCdUtEQmZpTXQ4T3RMYVdDcWYyd1E?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOdW9vVGJMNU10MHFIeWx1cG1mS0Y0NXQyR1pPbVIwNm0xc0hENFQ4bkp6bktTN0hMZnB4Q2l6TDFmcGk3NHBwYUQ3TFIxaUFxSVpnYXJwdS10OEJvWXpLMlVfMEtPNDMzWUZxOUR3MHJGNWt4M1UwU3FQTVhQUFVtQmJGT2NiYjF3azhRR0tFMzFVVzF5QVhZMkdB?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nuvation Bio\u2019s Valuation After Recent Share Price Swings", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ1Jma0pkbTdnN0J3NzJ4TlZOX2tJOHlCMFdsWVZfOUp2MGRYMFI5SEdocWZ6RG56QmljaHZKMlYwREZyY1JYcW5JRGxIV0NVMmtmNUJ3ZU9jOXVfSWFUcjNPLWpWai1pLTlJcm1fcVdvcmFhM2FJRGhFZTFxZWlfOTFILVY3c2hrbWR5TlBvMUdLbG1MQi1Bc0JXTF9iWXNW?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Data And Japan Rights Add Weight To Undervalued Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcWFFbVp4bVBPSndwZ3J1X3p2RUdUa2VIajNxM3NRSG9fb0xIRU5iNnNxVnJJYjdIUjdyR3lRbVlfQmJnM01hb3ZjUGJncFNtS3VBeWtWZ1ItbFFxWktjNUY4T3dTT25Pemg4NjRibkpJQU1hbTEyQVltYjFWeGYyczMyc3p6VHhXV1dqUGFUU2FSbFVtb2hqcnc1emQ5UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPc1ZsWjBKMnRYLXhhdGgxbGlRUVVETUdTa2l0TFN3dzN5NFIwMWFvV0RxT1pnZXpqWWs1LUJBWGl6RFJEWnRKY3FCSkdSMEJVRTBmSXpPNFJ3bjh2WU9iakY4QnNzNVBXUGk3TzBINW1ieWR0MGVXNmxEbE5pNmloZDlrRmozbFdZZmlHTE1aWV9TUDRRSTNOT3NEaw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Options Traders Betting on a Big Move in Nuvation Bio Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOS01ELTg0ek1VM3Q2Nk9vMHFDbGNrV0duNk1Oc1ZBb1RZaU85NHZzc2c3MmNyb2pmV1lEaWNBQmJjWFhrWDBOU0pibWc1cnFqQnJrZUo2WlhkeDUtdXBkR2dMMkVTdUtjaFBDdEpmOWQ1S05wQkl1UDFNRGp0LXA1Mi00WEpOYTFQa1hrY2txNWxXQkMyV1ZYbWt5d2J2akE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Nuvation Bio\u2019s Global Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1vWXJKRW5xNnpLZzRkRDltY1M0V0hualY2QVpNaW9Xc0NGSTlzSTZuWnZZUTJJVWNPYS1VZGxtbThmS1hlWmdVaEpFQ3BjMjhYQzhXY3BqSzlQclQ2Z1M4eVJtNUZfdDJiT3BF?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-07-15T10:03:15+00:00", "published_display": "15 Jul 2026 10:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPYlhzWHNLSkNucGJrb0ZONXhNZW1EVm13Y1kxSFo0c1U5OXdNLXd2bklIRW9hLVpWSHUzeU5nejB1UnFSV3lmdVNWM21ZdUhvcURjcy1HTnc5aGNXNjAySjVubnFmT1g3bVR0QUxnZzlWbTZvY3Y4Y3ZXZ3hZZ0RlS1d3TQ?oc=5", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-15T08:32:44+00:00", "published_display": "15 Jul 2026 08:32", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNWWRTSGJzRnIxYl9KNThLQU1kbUdua01DTU9aeUp0WWZHazl0QjlmaGtIdjNQTjE0QWFybnU1cHBxaVJHRG50MmUwdzZEOFhKRVFTeERjaTJSQjlDb3pPSklrU1BDV2kzYVJwNU00RmJtM05FQWNQUlRVRVkweUZwRzZWUUF0WXhTZTk3NkhDLXdBV0dYdTRfeERwcUhwaVRlWWNnUDhrZFRDSlhMZ2RvLVJWMTZGYmZXZWxuTi1OOEV5ZlBjNE5HSDJxQXJVcGhWMEZXMXV5bFhHUTNFUm5keQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-14T05:38:00+00:00", "published_display": "14 Jul 2026 05:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio (NUVB) Fairly Valued Following UK Taletrectinib Filing Progress?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-13T19:46:00+00:00", "published_display": "13 Jul 2026 19:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOcFBVVi1URkdvVmh0eGRWWUNYX1puemJTWnk4dEVza1JFS0xFREZnOEEwSUpYYnM5bkM3RElzVzRvb1NwVFdsQTlERzVNQ2QweldrM1hpaklrSVlsbGdNZFBBZG9XbTJCYlZINXRzS1pBMDdnRDdPTWxJeFdFclZBSHVaa2dCQXgtYXl3M3pTcWpxWmhZYmhv?oc=5", "source_name": "Market source", "published_at": "2026-07-13T09:28:51+00:00", "published_display": "13 Jul 2026 09:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE", "summary": "This page provides live quotes and charts for Nuvation Bio Inc. Class A (NUVB) stock, showing its current price of $6.11, an increase of $0.24 (4.09%). It indicates that analyst ratings and earnings information for NUVB are not currently available. The page also includes disclaim", "url": "https://timothysykes.com/quote/NUVB/", "source_name": "timothysykes.com", "published_at": "2026-07-10T00:40:28", "published_display": "10 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvation Bio (NUVB) Have the Global Scale to Maximize Taletrectinib\u2019s Regulatory Momentum?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T13:40:03+00:00", "published_display": "09 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-nuvation-bio-120838638.html", "source_name": "MT Newswires", "published_at": "2026-07-07T12:08:38+00:00", "published_display": "07 Jul 2026 12:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering", "summary": "Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or \"Greenshoe Exercise,\" to purchase an additional $37.5 million of its 0.75% Convertible Senior Notes due 2032. This brings the total offering to $287.5 million. The net proceeds,", "url": "https://sg.finance.yahoo.com/news/nuvation-bio-inc-announces-full-210900758.html", "source_name": "Market source", "published_at": "2026-07-06T21:13:52", "published_display": "06 Jul 2026 21:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total common shares outstanding of Nuvation Bio, Inc. Class A \u2013 FWB:1E30", "summary": "This article provides details on the total common shares outstanding for Nuvation Bio, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:1E30. It indicates that the market was closed with no trades when the information was accessed. The page also features ", "url": "https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/total-shares-outstanding/", "source_name": "TradingView", "published_at": "2026-07-04T05:10:16", "published_display": "04 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nuvation Bio, Inc. Class A \u2013 FWB:1E30", "summary": "This article provides financial information for Nuvation Bio, Inc. Class A (FWB:1E30) on the Frankfurt Stock Exchange. It specifically highlights the \"Price to earnings forward\" metric for the company. The page appears to be a financial data presentation without detailed analysis", "url": "https://www.tradingview.com/symbols/FWB-1E30/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T19:40:48", "published_display": "03 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Nuvation Bio, Inc. Class A Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Nuvation Bio, Inc. Class A stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment focuses inclu", "url": "https://www.tradingview.com/symbols/FWB-1E30/etfs/", "source_name": "TradingView", "published_at": "2026-07-03T17:09:47", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Nuvation Bio\u2019s (NUVB) U.K. Taletrectinib Milestone Hint at Durable Global Oncology Positioning?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOVTRnNV9aOEpROGdYbE9qZk1Hdm1TSmVPVXVtRXkzbHJEOVpRNm9RdEUzbmFOU1kyRzBHUG5LX0JRQkMwVG1hOTN1N3Y4NlZ4MTZtNzBHeWZ2Z3hXbGdrNG1TemU2enVxQXF2SDJ3R21UTkVfdVR2OFBWZ0VLZGtCU0JselZkQ0Z3a2dpY21MWENYczUyVERZTzduOHFXWnhnSGY2SjZsTE5uTzNfZUlpanE0TjA5TmlTSHBHWWtybHlZQ0o5cE81QkJvdUtMbERGRldHc1h2N2JxZHdz0gHiAUFVX3lxTE10dXVqMk5ncVVSQTNTbFQyOGxHd2djcVZnNW5ienJZcWdZWkpYWExZb3B2UktIOWVqQkJ2ZHZYR1d2Z3RrVVF0Mzl3MTBaOTFwR1hVbldwMmNpQWhlWEhvenVJRnRsUTlMQ0ZDMVFORVh1eF96Y29xOExaNTVKVWpES1ZVT0g2TjF5RUh6WWRZak9hc1FZVUhpVkgzd29FMFpyNFhNOHZrV3JLUUtpbjBrQmwtdmVWekpZR3ZzR0Jjck5HVW5TV2ZoeThJdHRZczhZRk85RndRSUJrbmZlUFVBeGc?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T10:42:51+00:00", "published_display": "01 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio\u2019s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZGJsT2ZOVS1aejJ2V3c2bnlab2RaWTN5TERlNmhmNVktUVllOURmbjk1ZEZxcE9KT0NhQ2lJODFERlk2VzNWT3pyMkdPV1JQTFdZaTBPVFBoSTVwWVRQb05PSVhIeEtsMUM1dEkzLWdYSlQta3hsSnB1TlpuellIckxYbVpwdFU2aWY3M1N1cFMxSVd3Q3VnbjZVUEM1dzY5OFppXw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nuvation-bio-faces-more-predictable-190809469.html", "source_name": "MT Newswires", "published_at": "2026-06-30T19:08:09+00:00", "published_display": "30 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?", "summary": "", "url": "https://finance.yahoo.com/m/0935449e-7333-36f6-afc0-633652ca661b/nuvation-bio-stock-is-up-190%25.html", "source_name": "Motley Fool", "published_at": "2026-06-29T23:39:05+00:00", "published_display": "29 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio's Taletrectinib Enters UK Regulatory Review", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nuvation-bio-apos-taletrectinib-enters-123720021.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:37:20+00:00", "published_display": "29 Jun 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio clears first U.K. regulatory step for lung cancer drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLXhDWVBKMGpuRVY5bTIyTTFZZmpQdTU0Sm0wVU9haml0bW4wVHRWNTZJVVl3Rm5YZ0tUN3NzZnktUlpPdHZGVmplWDByb2Q3SGJGSTdCTm9kNHVtRk9nQk8tT0szT0dseXhKRE9wbmhIdFp4S1diMWJvMWdrWDAzc0cydHozNGZMZDhJemZLZzVILUMzblpaZEdsdGF1MjVDVmwyVlRhUVJ6QnZNU0M5TVdmeDdRWHQw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB)", "summary": "This article provides an overview of Nuvation Bio Inc. (NYSE: NUVB) stock performance, financial estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnin", "url": "https://www.tradingview.com/symbols/NYSE-NUVB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:16", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes", "summary": "Nuvation Bio Inc. has announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due in 2032. The net proceeds, estimated at approximately $241.2 million, will be used to pay for capped call transactions, repay a senior secured l", "url": "https://www.prnewswire.com/news-releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes-302811504.html", "source_name": "PR Newswire", "published_at": "2026-06-26T04:10:55", "published_display": "26 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Announces Proposed Convertible Senior Notes Offering", "summary": "Nuvation Bio Inc. announced its intent to offer $200.0 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30.0 million. The company plans to use the proceeds to cover capped call transactions, repay its senior secured loan,", "url": "https://investingnews.com/nuvation-bio-announces-proposed-convertible-senior-notes-offering/", "source_name": "Investing News Network", "published_at": "2026-06-26T03:10:56", "published_display": "26 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio\u2019s chief people officer sells $753k in stock", "summary": "Nuvation Bio's Chief People Officer, Markel Stacy, sold 125,000 shares of Class A Common Stock for $753,187, following the exercise of stock options. This sale was part of a pre-arranged trading plan, occurring after the company's stock surged 215% over the past year. Nuvation Bi", "url": "https://m.investing.com/news/insider-trading-news/nuvation-bios-chief-people-officer-sells-753k-in-stock-93CH-4759410?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T23:10:26", "published_display": "25 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio prices $250M convertible notes offering", "summary": "Nuvation Bio Inc. has priced an upsized offering of $250 million in convertible senior notes due in 2032, increasing from a previously announced $200 million. The biotech company will use the proceeds to pay for capped call transactions, repay its existing senior secured loan of ", "url": "https://www.investing.com/news/company-news/nuvation-bio-prices-250m-convertible-notes-offering-93CH-4761987", "source_name": "Investing.com", "published_at": "2026-06-25T21:09:57", "published_display": "25 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio CFO Sauvage sells $286k in stock", "summary": "Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan. This transaction occurred after he exercised stock options to acquire the shares. Following the sale, Sauvage holds 12,673 direc", "url": "https://www.investing.com/news/insider-trading-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4759391", "source_name": "Investing.com", "published_at": "2026-06-25T13:40:16", "published_display": "25 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio CFO Sauvage sells $286k in stock By Investing.com", "summary": "Nuvation Bio Inc.'s CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan, after exercising stock options. Despite a significant stock surge, InvestingPro suggests the shares might be overvalued. Th", "url": "https://m.au.investing.com/news/stock-market-news/nuvation-bio-cfo-sauvage-sells-286k-in-stock-93CH-4503569?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-25T05:10:33", "published_display": "25 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio chief regulatory officer sells $379k in stock", "summary": "Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of company stock worth $379,190 on June 23, 2026, following the exercise of stock options. This sale was conducted under a 10b5-1 trading plan and comes after a significant 215% surge", "url": "https://m.investing.com/news/insider-trading-news/nuvation-bio-chief-regulatory-officer-sells-379k-in-stock-93CH-4759395?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T23:10:26", "published_display": "24 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Nuvation Bio Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQUlZ6dlB5Tkc1bkJTcTFmTTN1N3pSR3RFN3ZuajJlSUVZcXJGZUNMU2hyMDU3MFBKRzZfU1R3SXpsX0JtYzZxZWFDRUY2Rk5JR05WVWFuRURtNDhYZUNIb0Q4Um9FeVd4YVBNSVNhVEJtTTE4MHpLRmtuaXJTRVdneWtfem9Xa3JkY3pQYXQtSzM5QW5ZVkp5Nw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNdGpMbmRGd0g0eU9OanhzdTNGNlFIOF83dGszMmNnTXFTR0VVaEVTSkgtR2NzMkxjNmtFSmQ0eVdWbEtySElkMmh4VkRqLURHN1VvejFaclBNLVg1dElma2tQbW82aVU3Z3RIR1pqRHRhWGlKd3pXdjBVRVRCV2xvWGdZeFVfM2RoeFB1V2V4b0R1dHl1U044eWdhMnpzclhqLW1WNWZXMA?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio director Robert Mashal buys $118,250 in stock", "summary": "Robert Mashal, a director at Nuvation Bio Inc. (NASDAQ:NUVB), recently purchased 25,000 shares of the company\u2019s Class A Common Stock for $118,250 through his revocable trust. This transaction increases his indirect ownership to 225,000 shares. The purchase comes as InvestingPro a", "url": "https://www.investing.com/news/insider-trading-news/nuvation-bio-director-robert-mashal-buys-118250-in-stock-93CH-4738706", "source_name": "Investing.com", "published_at": "2026-06-12T00:39:09", "published_display": "12 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director\u2019s trust buys 25,000 Class A shares", "summary": "Nuvation Bio director Robert Mashal, through his revocable trust, purchased 25,000 shares of Class A Common Stock at $4.73 per share in an open-market transaction. This acquisition increases the trust's total holdings to 225,000 shares of Nuvation Bio Class A Common Stock. The tr", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-e33ac05134c3.html", "source_name": "Stock Titan", "published_at": "2026-06-11T23:39:29", "published_display": "11 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade) (NYSE:NUVB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPQ1MtQ3VidVdpNW03ZS1ubVFnVFZoeTdZTU91ZEY2RUFpdDliNmxQRXh3d0VJdlZpU1dQQTFfQUticXJrV1drNzZlS1A2dzEzc01ucTRFQUZhVHR3ejZVeVdRMm1xcWtxYUQ0eVF0Y1J0QTNyR1BKX2gtZWJaVjRNLXRKWUVSWFR0dkFSLXM2NkpyYXYxUTItVw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay", "summary": "Nuvation Bio Inc. (NUVB) announced the results of its 2026 Annual Meeting. Shareholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff, to serve until the 2029 annual meeting. Additionally, KPMG LLP was ratified as", "url": "https://www.stocktitan.net/sec-filings/NUVB/8-k-nuvation-bio-inc-reports-material-event-d1aee89d2c0a.html", "source_name": "Stock Titan", "published_at": "2026-05-28T14:39:04", "published_display": "28 May 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results", "summary": "Nuvation Bio Inc. filed an 8-K form with the SEC, detailing the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as auditor, and an advisory vote on executive compensation. The repor", "url": "https://www.minichart.com.sg/2026/05/28/nuvation-bio-inc-files-form-8-k-with-sec-detailing-company-information-and-annual-meeting-results/", "source_name": "Minichart", "published_at": "2026-05-28T11:40:08", "published_display": "28 May 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing", "summary": "Nuvation Bio Inc. director Xiangmin Cui's insider trading report has been corrected through an amended Form 4 filing, revealing he was granted 76,923 stock options for Class A common stock on February 27, 2026. This rectifies an administrative error in a previous filing that repo", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-a-nuvation-bio-inc-amended-insider-trading-activity-f55e98598bfa.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036", "summary": "Nuvation Bio (NUVB) director Xiangmin Cui was granted 123,397 stock options with an exercise price of $4.79 per share, expiring on May 20, 2036. These options represent a compensation-related acquisition and will fully vest on the earlier of May 21, 2026, or the next shareholder ", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-2f2714f8cd0c.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79", "summary": "Nuvation Bio Inc. director Robert B. Bazemore was granted 123,397 stock options for Class A common stock with an exercise price of $4.79 per share, expiring on May 20, 2036. The options will vest 100% on May 21, 2026, or the next annual shareholder meeting, contingent on his cont", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-ca8bf6a19015.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Nuvation Bio (NASDAQ: NUVB) awarded 123,397 stock options", "summary": "Robert Mashal, a director at Nuvation Bio (NASDAQ: NUVB), was granted 123,397 stock options with an exercise price of $4.79 per share. These options will vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, provided he maintains continuous service. Th", "url": "https://www.stocktitan.net/sec-filings/NUVB/form-4-nuvation-bio-inc-insider-trading-activity-079aaa1cf63f.html", "source_name": "Stock Titan", "published_at": "2026-05-27T00:10:36", "published_display": "27 May 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio to Present New Quality-of-Life Data for IBTROZI\u00ae (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting", "summary": "Nuvation Bio will present new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI\u00ae (taletrectinib) at the ASCO 2026 Annual Meeting. The data shows that 88% of patients with ROS1-positive non-small cell lung cancer (NSCLC) reported improved or stable quality ", "url": "https://www.prnewswire.com/news-releases/nuvation-bio-to-present-new-quality-of-life-data-for-ibtrozi-taletrectinib-in-patients-with-ros1-positive-non-small-cell-lung-cancer-at-asco-2026-annual-meeting-302782377.html", "source_name": "PR Newswire", "published_at": "2026-05-25T11:40:10", "published_display": "25 May 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) Proxy filing Summary", "summary": "Nuvation Bio (NUVB) has scheduled its Annual Meeting for May 21, 2026, where stockholders will vote on electing three directors, ratifying KPMG LLP as the auditor for 2026, and an advisory vote on executive compensation. The board recommends voting in favor of all proposals. The ", "url": "https://quartr.com/events/nuvation-bio-inc-nuvb-proxy-filing_FL4uRymA", "source_name": "Quartr", "published_at": "2026-05-18T22:10:08", "published_display": "18 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NYSE:NUVB) - Stock Analysis", "summary": "Nuvation Bio (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on cancer treatment. The company recently reported a surprise statutory profit in Q1 2026, exceeding analyst expectations, and its lead product candidate, IBTROZI (taletrectinib), has received FDA appr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio", "source_name": "Simply Wall Street", "published_at": "2026-05-14T20:15:24", "published_display": "14 May 2026 20:15", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio partners with Thermo Fisher for US drug manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTGpYVHRwR1hTVkxCRXFnRHQtRWF6NFBQMldMQk9KOUZPUC1WdkhBaWQxRFRHS3ZfTVJYVkNxSXFrRVlVR25ibmJwS2xydFVmbFE0UjNRbEMxbnJadFkxQm1DOElVNHpteEpLc1VUR0VuMWdFQlFkTmItVjB4YkhzbW1KT0puVkdNTW5fUzJldzBCXzJCaWhLS2U4RFYxeDhYdDdMSlJqN0xLLW90aGo3ckNFdTdzT0JFaG93bEl2eFY?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit", "summary": "Nuvation Bio Inc. (NYSE: NUVB) shares rose 8.1% after reporting a surprise profit of US$0.01 per share and revenues of US$83m for the first quarter, significantly exceeding analyst expectations. Analysts have increased their price target to US$12.33 and reduced their loss per sha", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/results-nuvation-bio-inc-confounded-analyst-expectations-wit", "source_name": "Simply Wall Street", "published_at": "2026-05-13T00:10:08", "published_display": "13 May 2026 00:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE8wX0hRWFNvTHlDNWhnNUNVYVl6ZGI4cVNacGFod3luQ1c3dHltakM4dlUxLXlPRFJiaVZsZXZLak9tVENHYy1sV1lrYm9NTGlNSjh2bjlKaGt0VlZLR282NmdzaHdnYzU4WVRaWUtHNkNYSkp3c24tMVZxT0RkOVE?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio's CEO and CFO line up four investor webcasts in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOQkYtczR5eG55VW5QbHBMekRHeEVCZ1BOZjN2Ni1QU1JwNjJiMThLMHVIYlpqMl9BbDlHT1VzMXo5LUNvVEExR184cE9fWWtBRTVGQ1E1RmQtSnJBWGdjXzNXbEdQVkdHSjAyM3Z2allzeXBzVHEwV1E2TlhvNUZMM284TVVrOWtZamRleWFMOThJZUdfOHNyZWkyMVo4NjRLSGMtS0FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNmdrLXhCLV90eHBKM0xwd0ZiLWdxbFo3QnhSZTJUd25LdjZydEo5NlN5OUZ0dXlCLWItamJBQkNFVWIzN1c3UlVBZDEwM1BHMlhscE9BSm5Eano4UjVuV2tfamowem1TX0dKbVk4S3NqNlU1a3B3blZUd2poTThiYl9xRzlNTXR3UXhSazFudWprNHNaM09CRzgxc2hqQUpadER3ODNTS0RQZWNoVVZOc0h2R0UtVzNRcVByT2t0MVZNRFFlZjVxQmtjNl9aQXhLUnVwaDNXSnVOUQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQV2paQ3gwTmhTZmRUT3RBMjRtUEYyR3VvWG5qaExJTDROaWdEa3ZoZk13N1NnTmU1SENxRk05aEVoa0JleWtsNkZldEpsekFERTRFVlhEbE84YWcwQTFPZlF0ZUFTbGcwb2xhd2RTa0VBLUdzU2l6d0JQUWZzcUloZERCdUtEQmZpTXQ4T3RMYVdDcWYyd1E?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOdW9vVGJMNU10MHFIeWx1cG1mS0Y0NXQyR1pPbVIwNm0xc0hENFQ4bkp6bktTN0hMZnB4Q2l6TDFmcGk3NHBwYUQ3TFIxaUFxSVpnYXJwdS10OEJvWXpLMlVfMEtPNDMzWUZxOUR3MHJGNWt4M1UwU3FQTVhQUFVtQmJGT2NiYjF3azhRR0tFMzFVVzF5QVhZMkdB?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Nuvation Bio\u2019s Valuation After Recent Share Price Swings", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ1Jma0pkbTdnN0J3NzJ4TlZOX2tJOHlCMFdsWVZfOUp2MGRYMFI5SEdocWZ6RG56QmljaHZKMlYwREZyY1JYcW5JRGxIV0NVMmtmNUJ3ZU9jOXVfSWFUcjNPLWpWai1pLTlJcm1fcVdvcmFhM2FJRGhFZTFxZWlfOTFILVY3c2hrbWR5TlBvMUdLbG1MQi1Bc0JXTF9iWXNW?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Data And Japan Rights Add Weight To Undervalued Story", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcWFFbVp4bVBPSndwZ3J1X3p2RUdUa2VIajNxM3NRSG9fb0xIRU5iNnNxVnJJYjdIUjdyR3lRbVlfQmJnM01hb3ZjUGJncFNtS3VBeWtWZ1ItbFFxWktjNUY4T3dTT25Pemg4NjRibkpJQU1hbTEyQVltYjFWeGYyczMyc3p6VHhXV1dqUGFUU2FSbFVtb2hqcnc1emQ5UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPc1ZsWjBKMnRYLXhhdGgxbGlRUVVETUdTa2l0TFN3dzN5NFIwMWFvV0RxT1pnZXpqWWs1LUJBWGl6RFJEWnRKY3FCSkdSMEJVRTBmSXpPNFJ3bjh2WU9iakY4QnNzNVBXUGk3TzBINW1ieWR0MGVXNmxEbE5pNmloZDlrRmozbFdZZmlHTE1aWV9TUDRRSTNOT3NEaw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Options Traders Betting on a Big Move in Nuvation Bio Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOS01ELTg0ek1VM3Q2Nk9vMHFDbGNrV0duNk1Oc1ZBb1RZaU85NHZzc2c3MmNyb2pmV1lEaWNBQmJjWFhrWDBOU0pibWc1cnFqQnJrZUo2WlhkeDUtdXBkR2dMMkVTdUtjaFBDdEpmOWQ1S05wQkl1UDFNRGp0LXA1Mi00WEpOYTFQa1hrY2txNWxXQkMyV1ZYbWt5d2J2akE?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 104, "total_relevant": 65, "sentiment_summary": {"positive": 20, "negative": 3, "neutral": 42, "score": 55, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 19.25, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}], "positive_events": 20, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 5.81, "latest_week": "2026-07-10", "one_week_move": 1.9, "four_week_move": 18.1, "twelve_week_move": 14.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.020068, "market_dynamics_buy_signal": false, "relative_strength": 4.85753, "fair_value_gap": 83.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.4936, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.9% over one week, +18.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.9% over one week, +18.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Nuvation Bio\u2019s Global Strategy"}], "updated_at": "2026-07-18T08:17:16.803229+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}